Assuntos
Infecções por HIV , Profilaxia Pré-Exposição , Doenças Bacterianas Sexualmente Transmissíveis , Infecções Sexualmente Transmissíveis , Humanos , Doxiciclina/uso terapêutico , Doenças Bacterianas Sexualmente Transmissíveis/epidemiologia , Doenças Bacterianas Sexualmente Transmissíveis/prevenção & controle , Infecções Sexualmente Transmissíveis/prevenção & controle , Infecções Sexualmente Transmissíveis/tratamento farmacológico , Infecções por HIV/prevenção & controle , Profilaxia Pós-ExposiçãoRESUMO
INTRODUCTION: Gaps in information about the safety and efficacy of COVID-19 vaccines in pregnancy have led to substantial global variation in public health guidance regarding the use of COVID-19 vaccines in pregnancy over the course of the pandemic. METHODS: We conducted systematic screenings of public health authorities' websites across 224 countries and territories every 3 weeks to track the development of policies on COVID-19 vaccine use in pregnancy. Policies were categorised using a 1-5 permissiveness scale, with 1 indicating policies that recommended use, and 5 indicating policies that recommended against use. RESULTS: As of 30 September 2021, 176 countries/territories had issued explicit guidance on COVID-19 vaccine use in pregnancy, with 38% recommending use, 28% permitting use, 15% permitting use with qualifications, 2% not recommending but with exceptions, and 17% not recommending use whatsoever. This represented a significant shift from May 2021, when only 6% of countries/territories with such policies recommended the use of COVID-19 vaccines in pregnancy (p<0.001). However, no policy positions could be found for 21% of all countries and territories, the vast majority being low and middle income. Policy positions also varied widely by vaccine product, with Pfizer/BioNTech and Moderna vaccines being most commonly recommended or permitted. CONCLUSION: Our study highlights the evolution of policies regarding COVID-19 vaccine use in pregnancy over a 5-month period in 2021, the role of pregnancy-specific data in shaping these policies and how inequities in access for pregnant people persist, both within countries and globally.
Assuntos
Vacinas contra COVID-19 , COVID-19 , COVID-19/prevenção & controle , Feminino , Humanos , Pandemias/prevenção & controle , Gravidez , Saúde Pública , SARS-CoV-2Assuntos
Custos de Medicamentos/legislação & jurisprudência , Política de Saúde , Medicina Estatal/legislação & jurisprudência , Análise Custo-Benefício , Custos e Análise de Custo , Acessibilidade aos Serviços de Saúde/história , História do Século XX , Humanos , Alocação de Recursos , Valores Sociais , Medicina Estatal/história , Reino Unido , Estados UnidosRESUMO
With a $3 billion investment by the federal government, the National Children's Study (NCS) recently began recruitment. The NCS is a golden-and potentially missed-opportunity to study one of the most underrepresented populations in clinical research: pregnant women. As the nation's largest-ever study of children's health, the NCS will examine the effects of the environment on children from before birth to 21 years of age, with participants sampled primarily through women during pregnancy. Thus the NCS presents a rare opportunity to study the health of women during and after pregnancy, in addition to the health of their children. On both moral and policy grounds, we make the case for inclusion of women's health outcomes in the NCS.
Assuntos
Promoção da Saúde/estatística & dados numéricos , Pesquisa sobre Serviços de Saúde/estatística & dados numéricos , Bem-Estar Materno/estatística & dados numéricos , Resultado da Gravidez , Cuidado Pré-Natal/estatística & dados numéricos , Medicina Baseada em Evidências , Feminino , Humanos , Gravidez , Marketing Social , Estados UnidosRESUMO
Because an influenza pandemic would create the most serious hardships for those who already face most serious hardships, countries should take special measures to mitigate the effect of a pandemic on existing social inequalities. Unfortunately, there is little evidence that anybody is thinking about that.